BACKGROUND: Childhood cancer survivors treated with cardiotoxic therapies are recommended to have routine cardiac assessment every 1 to 5 years, but the long-term benefits are uncertain. OBJECTIVE: To estimate the cost-effectiveness of routine cardiac assessment to detect asymptomatic left ventricular dysfunction and of angiotensin-converting enzyme inhibitor and β-blocker treatment to reduce congestive heart failure (CHF) incidence in childhood cancer survivors. DESIGN: Simulation model. DATA SOURCES: Literature, including data from the Childhood Cancer Survivor Study. TARGET POPULATION: Childhood cancer survivors. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Interval-based echocardiography assessment every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or β-blocker treatment for patients with positive test results. OUTCOME MEASURES: Lifetime risk for systolic CHF, lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The lifetime risk for systolic CHF among 5-year childhood cancer survivors aged 15 years was 18.8% without routine cardiac assessment (average age at onset, 58.8 years). Routine echocardiography reduced lifetime risk for CHF by 2.3% (with assessment every 10 years) to 8.7% (annual assessment). The ICER for assessment every 10 years was $111 600 per quality-adjusted life-year (QALY) compared with no assessment. Assessment every 5 years had an ICER of $117 900 per QALY, and ICERs for more frequent assessment exceeded $165 000 per QALY. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to treatment effectiveness, absolute excess risk for CHF, and asymptomatic left ventricular dysfunction asymptomatic period. The probability that assessment every 10 or 5 years was preferred at a $100 000-per-QALY threshold was 0.33 for the overall cohort. LIMITATION: Treatment effectiveness was based on adult data. CONCLUSION: Current recommendations for cardiac assessment may reduce CHF incidence, but less frequent assessment may be preferable.
BACKGROUND:Childhood cancer survivors treated with cardiotoxic therapies are recommended to have routine cardiac assessment every 1 to 5 years, but the long-term benefits are uncertain. OBJECTIVE: To estimate the cost-effectiveness of routine cardiac assessment to detect asymptomatic left ventricular dysfunction and of angiotensin-converting enzyme inhibitor and β-blocker treatment to reduce congestive heart failure (CHF) incidence in childhood cancer survivors. DESIGN: Simulation model. DATA SOURCES: Literature, including data from the Childhood Cancer Survivor Study. TARGET POPULATION: Childhood cancer survivors. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Interval-based echocardiography assessment every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or β-blocker treatment for patients with positive test results. OUTCOME MEASURES: Lifetime risk for systolic CHF, lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The lifetime risk for systolic CHF among 5-year childhood cancer survivors aged 15 years was 18.8% without routine cardiac assessment (average age at onset, 58.8 years). Routine echocardiography reduced lifetime risk for CHF by 2.3% (with assessment every 10 years) to 8.7% (annual assessment). The ICER for assessment every 10 years was $111 600 per quality-adjusted life-year (QALY) compared with no assessment. Assessment every 5 years had an ICER of $117 900 per QALY, and ICERs for more frequent assessment exceeded $165 000 per QALY. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to treatment effectiveness, absolute excess risk for CHF, and asymptomatic left ventricular dysfunction asymptomatic period. The probability that assessment every 10 or 5 years was preferred at a $100 000-per-QALY threshold was 0.33 for the overall cohort. LIMITATION: Treatment effectiveness was based on adult data. CONCLUSION: Current recommendations for cardiac assessment may reduce CHF incidence, but less frequent assessment may be preferable.
Authors: T R Möller; S Garwicz; L Barlow; J F Winther; E Glattre; G Olafsdottir; J H Olsen; R Perfekt; A Ritvanen; R Sankila; H Tulinius Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: M C Cardous-Ubbink; R C Heinen; N E Langeveld; P J M Bakker; P A Voûte; H N Caron; F E van Leeuwen Journal: Pediatr Blood Cancer Date: 2004-06 Impact factor: 3.167
Authors: Paul A Heidenreich; Matthew A Gubens; Gregg C Fonarow; Marvin A Konstam; Lynne W Stevenson; Paul G Shekelle Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong Journal: Cardiovasc Res Date: 2019-04-15 Impact factor: 10.787
Authors: Yan Chen; Eric J Chow; Kevin C Oeffinger; William L Border; Wendy M Leisenring; Lillian R Meacham; Daniel A Mulrooney; Charles A Sklar; Marilyn Stovall; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui Journal: J Natl Cancer Inst Date: 2020-03-01 Impact factor: 13.506
Authors: Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Daniel A Mulrooney; Gregory T Armstrong; Sujuan Huang; Kirsten K Ness; Matthew J Ehrhardt; Vijaya M Joshi; Juan Carlos Plana; Elsayed Z Soliman; Daniel M Green; Deokumar Srivastava; Aimee Santucci; Matthew J Krasin; Leslie L Robison; Melissa M Hudson Journal: Ann Intern Med Date: 2016-01-05 Impact factor: 25.391